ライフサイエンスコーパス: leukapheresis

1 CACs and EPCs were efficiently harvested by leukapheresis.

2 storing large numbers of angiogenic cells by leukapheresis.

3 lating factor (hG-CSF) and were collected by leukapheresis.

4 d to G-CSF, intravenous device insertion, or leukapheresis.

5 lood, and cytokine-elicited peripheral blood leukapheresis.

6 al blood mononuclear cells were harvested by leukapheresis.

7 (+) peripheral blood stem cells harvested by leukapheresis.

8 cells were collected using a novel method of leukapheresis.

9 By day 5 of leukapheresis, 63% of the patients treated with SCF plus

10 DPBSCs were obtained by leukapheresis after mobilization with granulocyte-colony

11 cturing quality standards for both mobilized leukapheresis and bone marrow, and reconstitute human ha

12 We utilized leukapheresis and countercurrent centrifugal elutriation

13 treatment with G-CSF for 5 days followed by leukapheresis and intravenous infusion of three doses of

14 ould be primed by various factors related to leukapheresis and mobilization that increase its associa

15 Patients underwent leukapheresis and subsequent lapuleucel-T infusion 2 day

16 (PBPC) were cytokine-mobilized, collected by leukapheresis, and cryopreserved using 5% dimethyl sulfo

17 lating factor, collected by peripheral blood leukapheresis, and purified away from contaminating lymp

18 cyte colony-stimulating factor, harvested by leukapheresis, and purified by magnetic-activated cell s

19 clear cells from mobilized blood obtained by leukapheresis at day 4 after initiation of G-CSF (G-PBMC

20 Leukapheresis began on day 5 of cytokine administration

21 We further show that diagnostic leukapheresis can be easily combined with the US Food an

22 receive APC8015F, a product made with frozen leukapheresis cells.

23 increased IL-1beta production in stimulated leukapheresis concentrates and peripheral blood samples

24 ral blood mononuclear cells were obtained by leukapheresis, depleted of monocytes, and cultured in th

25 Leukapheresis followed by a two-step cell isolation proc

26 taxel plus ifosfamide were administered with leukapheresis, followed by three cycles of carboplatin p

27 amide 6 g/m(2) were given 2 weeks apart with leukapheresis, followed by three cycles of carboplatin p

28 utaneous technique in 15 children undergoing leukapheresis for collection of autologous peripheral bl

29 CD8(+) T cells obtained by leukapheresis from 10 patients with disseminated HLA-A2.

30 QVOA on resting CD4(+) T cells obtained via leukapheresis from 37 human immunodeficiency virus (HIV)

31 eripheral blood mononuclear cells (PBMCs) by leukapheresis from a 55-year-old man with chronic HIV in

32 ral blood stem cells (PBSC) were obtained by leukapheresis from a human male donor after 4 days of ad

33 blood mobilized progenitor cells obtained by leukapheresis from both major histocompatibility complex

34 obilized progenitor cells (PBPC) obtained by leukapheresis from MHC-inbred miniature swine (n=6) were

35 blood mononuclear cells (PBMCs) derived from leukapheresis from patients enrolled in the Baltimore Lo

36 east 1.75x10(7) CD34 cells were harvested by leukapheresis from patients in each study cohort.

37 neutrophils in donors before centrifugation leukapheresis has rekindled interest in the potential cl

38 Between 1 and 11 x 10(6) DC were obtained by leukapheresis in all patients even after PBSCT.

39 Dendritic-cell precursors were harvested by leukapheresis in weeks 0, 4, 8, and 24, loaded ex vivo w

40 ear cell depletion by leukapheresis, or sham leukapheresis, in a double-blind fashion (15 volunteers

41 Because leukapheresis (LA) targets peripheral blood mononuclear

42 per day for 5 days followed by large-volume leukapheresis (LVL).

43 lded a median of 194 x 10(6) CD34+ cells per leukapheresis (n = 7).

44 uantify and compare Th1 and Th2 responses of leukapheresis-obtained peripheral blood mononuclear cell

45 were collected by 2-hour single-blood volume leukapheresis on 2 consecutive days at the time of hemat

46 or 5 microg x kg(-1) x d(-1) for 5 days with leukapheresis on the fifth day.

47 Cs from different sources (phlebotomy versus leukapheresis) or using total or resting CD4(+)T cells p

48 receive active mononuclear cell depletion by leukapheresis, or sham leukapheresis, in a double-blind

49 ved DC vaccines were prepared after a single leukapheresis procedure and administered intradermally a

50 cytokine-mobilized animals via an automated leukapheresis procedure demonstrated a 10-fold increase

51 median progenitor cell yield from the 3-day leukapheresis procedure.

52 d more CD8(+) effector memory T cells in the leukapheresis product compared with G-CSF alone.

53 with as much as a 4.0-fold enrichment in the leukapheresis product compared with G-CSF alone.

54 Similarly, CD34+ cells isolated from the leukapheresis product did not differ significantly in im

55 fold more CD34+ cells were isolated from the leukapheresis product of animals receiving G-CSF or G-CS

56 cells isolated from the bone marrow (BM) and leukapheresis product of cytokine-mobilized nonhuman pri

57 l the Provenge that could be prepared from a leukapheresis product.

58 ule generates higher CD34+ cell yield in the leukapheresis product.

59 unoadsorptive system from the BM, PB, and/or leukapheresis product.

60 CD14 cells derived from leukapheresis products (G-CD14 cells) suppressed alloant

61 marrow (NBM), umbilical cord blood (CB), and leukapheresis products (LP).

62 We found that supernatants of leukapheresis products (SLPs) of patients mobilized with

63 may be also qualitative differences between leukapheresis products and marrow.

64 the large proportion of monocytes present in leukapheresis products could contribute to the unexpecte

65 in why HSPCs from mobilized peripheral blood leukapheresis products engraft more quickly in patients

66 isolated CD34(+) cells from peripheral blood leukapheresis products infected under the same condition

67 Tumor cells were detected in leukapheresis products of eight patients: three in the G

68 CD14 monocytes isolated from leukapheresis products of Macacca mulatta were cultured

69 4+ cells were determined in one blood volume leukapheresis products of six normal individuals given G

70 Examination of the T-cell subsets in the leukapheresis products showed three different patterns:

71 ed before cytokine infusion, and one to five leukapheresis products were tested for the presence of t

72 were tumor-positive, and in eight patients, leukapheresis products were tumor-positive.

73 accumulation of these cells in the resulting leukapheresis products.

74 obilization blood samples were compared with leukapheresis products.

75 In addition to the potential for reduced leukapheresis-related morbidity and costs, SCF offers ad

76 (8 mg orally) given 12 hours before standard leukapheresis routinely results in the collection of app

77 Leukapheresis samples from four fully ART-suppressed, ch

78 ose of granulocytes obtainable with standard leukapheresis techniques has been inadequate.

79 nt donor stimulation regimens and suboptimal leukapheresis techniques.

80 A leukapheresis to obtain peripheral-blood mononuclear cel

81 A leukapheresis to obtain peripheral-blood mononuclear cel

82 Leukapheresis was performed beginning on day 5 of cytoki

83 Leukapheresis was performed on day 6, and yielded a medi

84 Donor leukapheresis was performed on the 5th postoperative day

85 Leukapheresis was performed on the final 3 days of cytok

86 Leukapheresis was performed to harvest peripheral-blood

87 of 240 mug/kg by subcutaneous injection, and leukapheresis was then initiated just 4 hours later.

88 lls obtained before and after vaccination by leukapheresis were analyzed using a fluorescence-based H

89 CD34-enriched cells from the leukapheresis were predominantly myeloid-committed, but

90 Leukapheresis yields averaged 2.8 x 10(8) peripheral blo

91 tration of G-CSF, has significantly enhanced leukapheresis yields.